Aktis Oncology, Inc.
AKTS • NASDAQ
Aktis Oncology, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Matthew Roden, with a market cap of $838.0M.
CEOMatthew Roden
Next Earnings
Upcoming earnings announcement for Aktis Oncology, Inc.
Date
Tuesday, May 12, 2026 (in a month)
Timing
Before Market Open (9:13 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.85
Revenue Estimate
$2.5M
Earnings History
Past 12 earnings reports for Aktis Oncology, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 2024 | Q1 2025 | -$0.04Est: -$0.11 | +63.6% | $9.0MEst: $7.3M | +23.3% |  10-Q |
| Oct 8, 2024 | Q4 2024 | -$1.14Est: -$0.10 | -1040.0% | $5.9MEst: $8.0M | -27.1% | 10-K/A |
| May 13, 2024 | Q3 2024 | -$0.14Est: -$0.12 | -16.7% | $7.5MEst: $8.6M | -12.2% | 10-Q |
| Feb 13, 2024 | Q2 2024 | -$0.19Est: -$0.18 | -5.6% | $7.0MEst: $7.0M | +0.4% | 10-Q |
| Nov 13, 2023 | Q1 2024 | -$0.27Est: -$0.18 | -50.0% | $7.0MEst: $7.1M | -1.1% | — |
| Sep 6, 2023 | Q4 2023 | -$0.21Est: -$0.17 | -23.5% | $8.3MEst: $8.4M | -1.3% | 10-K |
| May 8, 2023 | Q3 2023 | -$0.20Est: -$0.19 | -5.3% | $7.4MEst: $7.5M | -2.3% | 10-Q |
| Feb 7, 2023 | Q2 2023 | -$0.19Est: -$0.25 | +24.0% | $5.9MEst: $5.9M | -0.9% | 10-Q |
| Nov 14, 2022 | Q1 2023 | -$0.28Est: -$0.20 | -40.0% | $5.6MEst: $5.6M | +0.1% | — |
| Sep 12, 2022 | Q4 2022 | -$0.26Est: -$0.19 | -36.8% | $5.2MEst: $6.2M | -15.9% | — |
| May 2, 2022 | Q3 2022 | -$0.22Est: -$0.22 | 0.0% | $4.6MEst: $4.7M | -2.0% | — |
| Jan 31, 2022 | Q2 2022 | -$0.23Est: -$0.20 | -15.0% | $3.7MEst: $3.8M | -2.9% | — |